Bristol-Myers Squibb Rights
CELG.RT
17 hedge funds and large institutions have $37.9K invested in Bristol-Myers Squibb Rights in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
51% more capital invested
Capital invested by funds: $25.1K → $37.9K (+$12.8K)
6% less funds holding
Funds holding: 18 → 17 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$1.96K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$502 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.01K |
| 2 |
VF
Virtu Financial
New York
|
-$1K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$186 |
| 4 |
Wells Fargo
San Francisco,
California
|
-$2 |
CELG.RT Hedge Fund Activity: Q1 2026 in Review
17 of the 8,150 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Rights (CELG.RT) for Q1 2026, worth a combined $37.9K — up 51% from $25.1K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CELG.RT and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $1.96K. The largest seller was Citadel Advisors, exiting entirely with an estimated $2.01K sold.
- 17 institutional investors held Bristol-Myers Squibb Rights (CELG.RT) as of Q1 2026, down from 18 in Q4 2025.
- Funds reported $37.9K of Bristol-Myers Squibb Rights stock for Q1 2026, up 51% quarter-over-quarter.
- 1 fund opened new Bristol-Myers Squibb Rights positions in Q1 2026 and 2 closed out, a net change of -1 holder.
- The largest Bristol-Myers Squibb Rights buyer in Q1 2026 was Two Sigma Securities, an estimated $1.96K added.
- The largest Bristol-Myers Squibb Rights seller in Q1 2026 was Citadel Advisors, an estimated $2.01K sold.
Based on aggregated 13F filings for Q1 2026.